Answers are grounded in this paper and cite their sources.
Comprehensive analysis identified novel compounds that selectively inhibit BACE1, suggesting new therapy options for Alzheimer's disease.
Alzheimer's disease (AD) remains a major neurodegenerative disorder with limited therapeutic medication. Despite intensive efforts, the clinical development of β‐site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors has been hindered by off‐target effects, poor brain penetration, and toxicity, which is often due to a lack of selectivity over BACE2. In this study, we conducted a comprehensive analysis of over 9,000 reported BACE1 inhibitors to identify key physicochemical properties and interaction fingerprints associated with effective binding. These criteria were used to filter a library of 1.4 million commercially available compounds, prioritizing candidates with better safety and blood‐brain barrier (BBB) permeability properties. The top‐ranked molecules were evaluated through molecular docking and molecular dynamics (MD) simulations, followed by selectivity assessments against BACE2 and additional off‐targets. Among these, two compounds, MCULE‐5138978734 and MCULE‐2333131051, exhibited strong and stable binding to BACE1 with markedly reduced affinity for BACE2, suggesting improved selectivity. This integrative in silico framework demonstrates a rational strategy for the discovery of selective BACE1 inhibitors and highlights promising lead candidates for further experimental validation in the development of AD therapeutics.
No takes yet. Share an insight, caveat, or question.
Varma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: